{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.1","value":"-4.5"},{"groupId":"OG001","spread":"1.6","value":"0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"title":"Body image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.7","value":"-0.2"},{"groupId":"OG001","spread":"1.0","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"title":"Sexual functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.3","value":"12.7"},{"groupId":"OG001","spread":"1.9","value":"11.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"title":"Future perspective"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"sexual enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.68","value":"8.15"},{"groupId":"OG001","spread":"0.98","value":"3.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"title":"Systemic therapy side effects"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.64","value":"-6.12"},{"groupId":"OG001","spread":"0.93","value":"-6.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"title":"Breast symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.87","value":"-1.14"},{"groupId":"OG001","spread":"1.27","value":"-2.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"title":"Arm symptoms"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"upset by hair loss"}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"description":"The EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side effects, breast symptoms, arm symptoms, upset by hair loss). QLQ-BR23 questionnaire employs 4-point scales with responses from: 1, \"Not at all\"; 2, \"A little\"; 3, \"Quite a bit\"; to 4, \"Very much\". All scores are converted to a 0 to 100 scale. A higher score representing a higher (\"better\") level of functioning (BR23: body image, sexual functioning, future perspective), or a higher (\"worse\") level of symptoms. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\\*Visit and Baseline.","dispersionType":"Standard Error","groups":[{"description":"150 mg Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG000","title":"Abemaciclib + NSAI"},{"description":"Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG001","title":"Placebo + NSAI"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline, End of Study (Up to 32 Months)","title":"Change From Baseline to End of Study in Symptom Burden on the EORTC QLQ-Breast23 Questionnaire","type":"SECONDARY","unitOfMeasure":"score on a scale"}